Theranos Overview

  • Founded
  • 2003
Founded
  • Status
  • Out of Business
  • Employees
  • 60
Employees
  • Latest Deal Type
  • Liquidation

Theranos General Information

Description

Developer of bio-monitoring systems designed to facilitate small-sample collection, testing and rapid communication of diagnostic information.The company's proprietary miniLab created an integrated infrastructure for real-time testing, decision making and individualized therapy, enabling laboratories to process early detection and intervention.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Monitoring Equipment
Primary Office
  • 1701 Page Mill Road
  • Palo Alto, CA 94304
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Theranos Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Bankruptcy: Liquidation 05-Sep-2018 00000 Completed Out of Business
9. Debt - General 23-Dec-2017 00000 00000 Completed Generating Revenue/Not Profitable
8. Secondary Transaction - Private 27-Mar-2017 00000 Completed Generating Revenue/Not Profitable
7. Later Stage VC (Series C3) 01-Oct-2015 00000 000.00 Cancelled Generating Revenue/Not Profitable
6. Later Stage VC (Series C2) 04-Feb-2014 00000 00000 00.00 Completed Generating Revenue/Not Profitable
5. Later Stage VC (Series C1) 28-Mar-2013 0000 00000 00.000 Completed Generating Revenue/Not Profitable
4. Later Stage VC (Series C1) 08-Jul-2010 0000 000.00 00.000 Completed Generating Revenue/Not Profitable
3. Later Stage VC (Series C) 15-Nov-2006 000.00 000.00 00000 Completed Startup
2. Early Stage VC (Series B) 16-Feb-2006 $9.1M $16M 0000 Completed Startup
1. Early Stage VC (Series A) 30-Mar-2005 $6.95M $6.95M 000.00 Completed Startup
To view Theranos’s complete valuation and funding history, request access »

Theranos Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C3 00,000,000 00.000000 000 000 00 000 0.000
Series C2 00,000,000 00.000000 000 000 00 000 00.000
Series C1 00,000,000 00.000000 00 00 00 00 0.000
Series C 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series B 54,162,965 $0.000100 $0.18 $0.18 1x $0.18 10.03%
Series A 46,320,045 $0.000100 $0.15 $0.15 1x $0.15 8.58%
To view Theranos’s complete cap table history, request access »

Theranos Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of bio-monitoring systems designed to facilitate small-sample collection, testing and rapid communication of d
Monitoring Equipment
Palo Alto, CA
60 As of 2018
00000
000000000000 00000

00000000

sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nos
0000000000 000000000
Austin, TX
00 As of 0000
00000
00000000000 00000

00000 00

abore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nis
0000000000 000000000
Saint Paul, MN
000 As of 0000
000.00
000000000 - 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Theranos Competitors (6)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Everlywell Venture Capital-Backed Austin, TX 00 00000 00000000000 00000
00000 0000000 Venture Capital-Backed Saint Paul, MN 000 000.00 000000000 - 000.00
000000 Formerly VC-backed Union City, CA 000 000.00 000000&0 000.00
00000 00000000000 Formerly VC-backed Sydney, Australia 00 000.00 00000000 000.00
00000000 000000 Formerly VC-backed York, United Kingdom 00 000.00 00000000 000.00
To view Theranos’s complete competitors history, request access »

Theranos Executive Team (18)

Name Title Board Seat Contact Info
Elizabeth Holmes Founder & Chief Executive Officer
Seth Michelson Ph.D Chief Scientific Officer & Principal Scientist, Biomathematician
Henry Kissinger Founder & Chief Executive Officer
Patrick O'Neill Chief Creative Officer
David Taylor Chief Executive Officer & General Counsel
You’re viewing 5 of 18 executive team members. Get the full list »

Theranos Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial